News

Dr. Reddy’s is featured in an article of Global Pharma Insights on “Nitrosamine contamination: pharma’s re-evaluation of its supply chain”

April 2020

Dr. Reddy’s was one of the very first API manufacturers to instigate a complete review to ensure that nitrosamine impurities are avoided by design and analytical methods are in place which meet the future stringent limits which have been set by regulatory agencies.

On winning the API Supplier of the Year award at the Generics Bulletin’s Annual Global Generics & Biosimilars Awards 2019, Dr. Reddy’s was also commended on the proactive and methodical approach followed to address the nitrosamine impurities situation with Sartan APIs (such as Valsartan).

In the article, Rajesh Sadanandan, Region Head – North America & Europe API, Dr Reddy’s, explained that pharma companies, API suppliers and ingredients manufacturer with a strong patient-focused culture are typically best positioned to anticipate and respond to these challenges, which ultimately will increase both access to high quality medications as well as patient health.”

Read the complete article here:

https://www.globalpharmainsights.com/manufacturing-outsourcing/nitrosamine-contamination-pharmas-re-evaluation-its-supply-chain

You can also read our whitepaper on “Meeting the New Regulatory Requirements in Sartan API Production” by clicking here:

https://api.drreddys.com/white-paper/meeting-new-regulatory-requirements-sartan-api-production-0

Email us: api@drreddys.com
+91 40 49002253

Contact Us

Please fill in the following form and we'll get back to you shortly.

* I agree and accept the Privacy Policy and Terms of Use of this website.

Email us: api@drreddys.com | +91 40 49002222

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.